Johnson & Johnson (JNJ) announced Wednesday the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies.
from RTT - Biotech https://ift.tt/3iX3DUO
via IFTTT
No comments:
Post a Comment